DeepMed Research

Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
HER2-negative Breast Cancer
Advanced Solid Tumors
Metastatic Colon Cancer
Metastatic Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Rectal Cancer

Interventions: Drug: Fruquintinib (HMPL-013)

First Posted Date: 2017-08-16

Last Posted Date: 2023-02-10

Lead Sponsor: Hutchmed

Target Recruit Count: 129

Registration Number: NCT03251378

Locations: 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 6 locations

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Fruquintinib
Drug: Gefitinib

First Posted Date: 2016-11-29

Last Posted Date: 2019-11-15

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 50

Registration Number: NCT02976116

Locations: 🇨🇳
The First Hospital of Zhejiang University, Hangzhou, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: NSCLC

Interventions: Drug: Placebo
Drug: Fruquintinib

First Posted Date: 2016-02-25

Last Posted Date: 2019-02-12

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 527

Registration Number: NCT02691299

Locations: 🇨🇳
The First Affiliated Hosptial of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
307 Hospital of PLA, Beijing, Beijing, China

and more 8 locations

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: fruquintinib

First Posted Date: 2016-02-24

Last Posted Date: 2020-02-13

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 6

Registration Number: NCT02689752

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Fruquintinib

First Posted Date: 2015-10-29

Last Posted Date: 2020-02-13

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 91

Registration Number: NCT02590965

Locations: 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Xi Nan Hospital, Third Military Medical University, Chongqing, Chongqing, China

and more 9 locations

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: placebo
Drug: fruquintinib

First Posted Date: 2014-12-11

Last Posted Date: 2020-02-17

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 416

Registration Number: NCT02314819

Locations: 🇨🇳
Hutchison Medi Pharma Investigational Site, Hangzhou, Zhejiang, China
🇨🇳
Hutchison Medi Pharma investigational site, Shenzhen, Guangdong, China
🇨🇳
Hutchison Medi pharma Investigational Site, Beijing, Beijing, China

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: placebo
Drug: fruquintinib

First Posted Date: 2014-07-22

Last Posted Date: 2020-06-16

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 71

Registration Number: NCT02196688

Locations: 🇨🇳
Hutchison Medi Pharma Investigational Site, Shanghai, China
🇨🇳
Hutchison Medi Pharma, Harbin, Heilongjiang, China

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: fruquintinib

First Posted Date: 2013-11-03

Last Posted Date: 2020-02-17

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 62

Registration Number: NCT01975077

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Phase 1

Completed

Conditions: Food Effect of Fruquintinib in Health Subjects

Interventions: Drug: fruquintinib

First Posted Date: 2013-10-07

Last Posted Date: 2020-02-17

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 20

Registration Number: NCT01955304

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumor

Interventions: Drug: Fruquintinib

First Posted Date: 2012-07-20

Last Posted Date: 2020-02-17

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 40

Registration Number: NCT01645215

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy